CoreCap Advisors LLC Boosts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

CoreCap Advisors LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2,295.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,668 shares of the biopharmaceutical company's stock after purchasing an additional 23,638 shares during the period. CoreCap Advisors LLC's holdings in Gilead Sciences were worth $2,279,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Principal Financial Group Inc. lifted its holdings in shares of Gilead Sciences by 4.3% during the third quarter. Principal Financial Group Inc. now owns 1,451,249 shares of the biopharmaceutical company's stock worth $121,673,000 after buying an additional 59,181 shares during the last quarter. Nordea Investment Management AB boosted its stake in shares of Gilead Sciences by 6.3% in the 4th quarter. Nordea Investment Management AB now owns 770,870 shares of the biopharmaceutical company's stock valued at $71,113,000 after purchasing an additional 45,507 shares during the last quarter. Diversified Trust Co increased its holdings in Gilead Sciences by 3.0% in the fourth quarter. Diversified Trust Co now owns 34,455 shares of the biopharmaceutical company's stock valued at $3,183,000 after purchasing an additional 1,019 shares during the last quarter. First Hawaiian Bank increased its position in shares of Gilead Sciences by 0.3% in the 4th quarter. First Hawaiian Bank now owns 56,115 shares of the biopharmaceutical company's stock valued at $5,183,000 after buying an additional 177 shares in the last quarter. Finally, ORG Partners LLC boosted its holdings in shares of Gilead Sciences by 0.3% in the fourth quarter. ORG Partners LLC now owns 66,317 shares of the biopharmaceutical company's stock valued at $6,126,000 after buying an additional 225 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of GILD stock traded down $1.30 on Friday, reaching $96.86. The company's stock had a trading volume of 13,140,489 shares, compared to its average volume of 7,595,228. The stock's fifty day simple moving average is $107.23 and its 200-day simple moving average is $99.23. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The company has a market capitalization of $120.61 billion, a price-to-earnings ratio of 261.78, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business's revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.32) earnings per share. Analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 3.26%. Gilead Sciences's payout ratio is 66.53%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the sale, the chief financial officer now owns 169,061 shares of the company's stock, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last three months, insiders sold 160,605 shares of company stock valued at $16,718,136. Insiders own 0.27% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Bank of America raised their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a research note on Thursday, February 13th. The Goldman Sachs Group increased their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Oppenheimer decreased their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.